TD Cowen lowered the firm’s price target on Jazz Pharmaceuticals (JAZZ) to $195 from $200 and keeps a Buy rating on the shares. The firm said total Q3 revenue came above expectations supported by beats from Xywav Epidiolex Defitelio and Zepzelca.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JAZZ:
- Jazz Pharmaceuticals price target raised to $182 from $172 at BofA
- Jazz Pharmaceuticals price target lowered to $195 from $200 at TD Cowen
- Jazz Pharmaceuticals price target lowered to $190 from $200 at Barclays
- Zymeworks upgraded to Outperform from Market Perform at Leerink
- Jazz Pharmaceuticals Reports Strong Q3 2024 Growth